Aavant Research vs Peptide Technologies
Independent side-by-side comparison across the 0 peptides both vendors sell. Composite scores, lab quality, and verified pricing.
Aavant Research
A grades on Tirzepatide (9 tests, avg 8.7) and Semaglutide (11 tests). Tighter score consistency than top peers.
Aavant Research full review →Peptide Technologies
5 BPC-157 tests with score variance 5.0–10.0. GHK-Cu and Ipamorelin coverage solid.
Peptide Technologies full review →Side-by-side breakdown
| PEPTIDE | AAVANT RESEARCH | PEPTIDE TECHNOLOGIES | WINNER |
|---|---|---|---|
| Tirzepatide |
8.7
B+ (9 tests)
|
—(not sold)
|
Aavant Research only |
| Retatrutide |
8.5
B+ (8 tests)
|
—(not sold)
|
Aavant Research only |
| Semaglutide |
8.5
B+ (11 tests)
|
—(not sold)
|
Aavant Research only |
| Ipamorelin |
8.2
B+ (5 tests)
|
—(not sold)
|
Aavant Research only |
| GHK-Cu |
—(not sold)
|
7.4
B (6 tests)
|
Peptide Technologies only |
| BPC-157 |
—(not sold)
|
6.5
B (5 tests)
|
Peptide Technologies only |
Which to choose
Across the 0 peptides both vendors sell, Aavant Research scores higher on 0, Peptide Technologies scores higher on 0, and 0 are within 0.3 points (effectively tied). Peptide Technologies additionally sells GHK-Cu, BPC-157; Aavant Research does not. Aavant Research additionally sells Tirzepatide, Retatrutide, Semaglutide, Ipamorelin; Peptide Technologies does not.
Composite scores reflect lab quality, sentiment, COA transparency, reliability, and price. How we score.
Full profiles: Aavant Research review · Peptide Technologies review